William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA(1) positive operations in Q3 2025 and expects to achieve strong ...

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

French biotech (ABVX) has emerged as the most likely acquisition target among biotechs in 2026, significantly outpacing others, while liver drug developer Madrigal Pharmaceuticals (MDGL) has become ...

Abivax ($ABVX), a French biotech firm, has become the top acquisition candidate among biotechs in 2026, according to a Truist ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Something remarkable is happening in Chinese biotech, and it’s happening fast. The country’s drug developers are learning to ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...